ALK and neoplasm: First line treatment for patients with metastatic NSCLC whose tumors have high PD‐L1 expression (TPS ≥ 50%) as determined by an FDA‐approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC [11]